In line with these findings, inhibiting both STAT3 activity (through addition of stattic, a STAT3 inhibitor) and conversion of Gln into glutamate (through BPTES, a glutaminase inhibitor) results in a pronounced reduction of viability in high‐invasive cancer cells (Fig 6J). The gene discussed is STAT3; the disease is cancer.